A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a - PubMed (original) (raw)
Clinical Trial
doi: 10.1093/annonc/mdr336. Epub 2011 Jul 16.
Affiliations
- PMID: 21765178
- DOI: 10.1093/annonc/mdr336
Free article
Clinical Trial
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
K N Chi et al. Ann Oncol. 2012 Jan.
Free article
Abstract
Background: The purpose of this study was to determine the clinical activity of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Patients and methods: Eligible patients had progressive disease within 6 months of receiving docetaxel. Patupilone was administered 10 mg/m2 i.v. every 3 weeks. The primary end point was the proportion of patients with a confirmed≥50% prostate-specific antigen (PSA) decline.
Results: Eighty-three patients were enrolled. At baseline, the median time to progression after prior docetaxel was 1.4 months (range 0-5.7). Gastrointestinal serious adverse events occurred in four of the six initial patients leading to a reduction of the starting dose of patupilone to 8 mg/m2 for subsequent patients. Grade 3-4 toxicity at this dose included diarrhea (22%), fatigue (21%), and anorexia (10%). One patient experienced grade 3-4 hematologic toxicity. A PSA decline of ≥50% occurred in 47% of patients. A partial measurable disease response occurred in 24% of assessable patients. A patient-reported pain response was observed in 59% of assessable patients. Median time to PSA progression was 6.1 months [95% confidence interval (CI) 4.7-8.0] and median overall survival was 11.3 months (95% CI 9.8-15.4).
Conclusions: Patupilone at 8 mg/m2 was tolerable, had antitumor activity, and was associated with symptomatic improvement in patients previously treated with docetaxel.
Similar articles
- Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer.
Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Hussain A, et al. Ann Oncol. 2009 Mar;20(3):492-7. doi: 10.1093/annonc/mdn665. Epub 2008 Dec 15. Ann Oncol. 2009. PMID: 19087985 Clinical Trial. - A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN. Azad AA, et al. Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29. Prostate. 2014. PMID: 25175831 - Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Rosenberg JE, et al. J Clin Oncol. 2009 Jun 10;27(17):2772-8. doi: 10.1200/JCO.2008.19.8002. Epub 2009 Apr 6. J Clin Oncol. 2009. PMID: 19349545 Free PMC article. - Epothilones in prostate cancer: review of clinical experience.
Dawson NA. Dawson NA. Ann Oncol. 2007 Jul;18 Suppl 5:v22-7. doi: 10.1093/annonc/mdm175. Ann Oncol. 2007. PMID: 17656558 Review. - Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
Beardsley EK, Chi KN. Beardsley EK, et al. Curr Opin Support Palliat Care. 2008 Sep;2(3):161-6. doi: 10.1097/SPC.0b013e32830c48a3. Curr Opin Support Palliat Care. 2008. PMID: 18685415 Review.
Cited by
- Novel non-AR therapeutic targets in castrate resistant prostate cancer.
Toren PJ, Gleave ME. Toren PJ, et al. Transl Androl Urol. 2013 Sep;2(3):265-77. doi: 10.3978/j.issn.2223-4683.2013.09.09. Transl Androl Urol. 2013. PMID: 26816739 Free PMC article. Review. - Crosstalk between Microtubule Stabilizing Agents and Prostate Cancer.
Chen QH. Chen QH. Cancers (Basel). 2023 Jun 23;15(13):3308. doi: 10.3390/cancers15133308. Cancers (Basel). 2023. PMID: 37444418 Free PMC article. Review. - Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial.
Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, Delord JP, Cerman J Jr, Salazar R, Dvorak J, Sguotti C, Urban P, Viraswami-Appanna K, Tan E, Tabernero J. Melichar B, et al. Br J Cancer. 2011 Nov 22;105(11):1646-53. doi: 10.1038/bjc.2011.438. Epub 2011 Oct 25. Br J Cancer. 2011. PMID: 22027708 Free PMC article. Clinical Trial. - Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
Antonarakis ES, Armstrong AJ. Antonarakis ES, et al. Prostate Cancer Prostatic Dis. 2011 Sep;14(3):192-205. doi: 10.1038/pcan.2011.23. Epub 2011 May 17. Prostate Cancer Prostatic Dis. 2011. PMID: 21577234 Free PMC article. Review. - Natural products: a continuing source of novel drug leads.
Cragg GM, Newman DJ. Cragg GM, et al. Biochim Biophys Acta. 2013 Jun;1830(6):3670-95. doi: 10.1016/j.bbagen.2013.02.008. Epub 2013 Feb 18. Biochim Biophys Acta. 2013. PMID: 23428572 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous